Intra-Cellular Therapies Inc reports results for the quarter ended in September - Earnings Summary

Intra-Cellular Therapies

03/11/2022 13:32

* Intra-Cellular Therapies Inc  ITCI.OQ  reported a
quarterly
adjusted loss of 57 cents​​ per share for the quarter ended in
September. The mean expectation of thirteen analysts for the
quarter was for a loss of 81 cents per share.
    * Revenue rose 223.6% to $71.87 million from a year ago;
analysts
expected $66.00 million. 
    * Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 57 cents​.
    * The mean earnings estimate of analysts had fallen by
about 17.2%
in the last three months.​ 
    * In the last 30 days three analysts negatively revised
earnings
estimates 
    * Intra-Cellular Therapies Inc shares had fallen by 1.5%
this
quarter and lost 12.4% so far this year.
    * The company reported a quarterly loss of $53.51 million.
    * Wall Street's median 12-month price target for
Intra-Cellular
Therapies Inc is $67.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 01:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.81          -0.57          Beat
 Jun. 30 2022      -0.76          -0.92          Missed
 Mar. 31 2022      -0.92          -0.78          Beat
 Dec. 31 2021      -0.99          -1.05          Missed